Deutsche Bank analyst Brad Zelnick maintains Okta (NASDAQ:OKTA) with a Buy and raises the price target from $80 to $90.
Achieve Life Sciences Announces Publication Of Cytisinicline Vaping Cessation Trial Results In JAMA Internal Medicine; Phase 2 ORCA-V1 Trial Showed Treatment With Cytisinicline More Than Doubled Odds Of Quitting E-Cigarettes Compared With Placebo
Phase 2 ORCA-V1 trial showed treatment with cytisinicline more than doubled odds of quitting e-cigarettes compared with placebo Cytisinicline treatment well tolerated with no serious adverse events
